Navigation Links
Michael J. Fox Foundation for Parkinson's Research Commits up to $2 million to Visualize Alpha-Synuclein Protein in the Brain
Date:6/3/2008

Funding to be issued under second round of Critical Challenges in Parkinson's Disease initiative

NEW YORK, June 3 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research is committing up to $2 million to develop and test non-invasive imaging technologies that would allow scientists to visualize pathological clumping of the PD-implicated protein alpha-synuclein in the living brain. Such techniques hold potential to serve as critically needed biomarkers to improve diagnosis and speed the development of treatments with potential to slow or stop the disease from progressing.

The funding is available to academic and industry researchers under the Foundation's Critical Challenges in Parkinson's Disease program, a key tactic in MJFF's ongoing quest to do whatever it takes to speed development of transformative treatments and a cure for Parkinson's disease. Critical Challenges is emblematic of the Foundation's urgent work to identify and prioritize research questions whose answers hold the greatest potential to move the dial on the development of better treatments and a cure for PD.

Alpha-synuclein is a major constituent of Lewy bodies, protein clumps that are the pathological hallmark of PD. The protein's function in the normal brain and the specific role it may play in PD remain unclear. It is believed that alpha-synuclein pathology (including clumping) may predate the onset of motor dysfunction in people with PD.

"Non-invasive technologies allowing scientists to observe alpha-synuclein pathology in the living Parkinson's brain could transform the landscape of PD research," said Katie Hood, MJFF CEO. "This program is a natural complement to our ongoing work to drive development of a PD biomarker to improve diagnosis and speed development of disease-modifying therapies."

In the absence of a known PD biomarker, Ms. Hood added, diagnosis of Parkinson's is subjective. Even a movement disorders specialist can make only a subjective diagnosis, and the rate of misdiagnosis is high, particularly in the early stages of the illness. Biomarkers are also a critical missing link in the development of treatments that could slow or stop the disease from progressing, since researchers currently have no reliable way to measure disease progression or track treatment effects over time.

Brian Fiske, PhD, associate director of research programs at MJFF, noted that the program would also benefit the field's current intensive efforts to therapeutically target alpha-synuclein. "New approaches in the pipeline seek to target abnormal alpha-synuclein and block its potential PD-causing effects. Having a method to visualize alpha-synuclein clumping in the brain as well as to watch it disappear after treatment would provide drug makers with a critical tool." Some of the very chemicals being developed to target alpha-synuclein could also be modified to become imaging agents as well, added Fiske. "There is the potential for cross-talk between the two parallel efforts."

Ideal applications will focus on developing and testing a sensitive and selective technique to image alpha-synuclein pathology in the living brain. Depending on the technology's stage of development, studies may use relevant animal models of Parkinson's disease or may perform human testing if the technology has met approved safety requirements. Applicants may propose studies exploiting standard or novel imaging modalities. The Foundation recommends that applicants refer to the development of amyloid imaging agents for Alzheimer's disease as a model for the development of alpha-synuclein imaging technologies.

Since successful applications to this program will likely require multiple areas of expertise, such as clinical and neuropathological knowledge of Parkinson's disease, protein and medicinal chemistry, imaging expertise and animal modeling, collaborations will be a major criterion for success. Team members may come from within or outside the PD research field.

The Foundation has earmarked up to $2 million in total funding for projects of up to two years. Applicants should submit a 'Technology Summary' containing an overall description of the proposed strategy for visualizing alpha-synuclein in the brain and the requirements for advancing the technology. These summaries must be submitted online by July 24, 2008, for review by the Foundation's scientific staff and a panel of scientific experts. Information about submitting a Technology Summary online can be found on the Foundation's Web site (http://www.michaeljfox.org). Applicants whose summaries are determined to meet the review criteria will work with MJFF staff to develop a full proposal. Funding is anticipated by December 2008.

A conference call with MJFF Research Programs staff to further clarify the aims and goals of this initiative will be held Friday, June 13, at 12 p.m. U.S. Eastern Time. Researchers wishing to participate in the call must RSVP to conferencecalls@michaeljfox.org and will receive an e-mail reply with call-in details.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the coming decade through an aggressively funded research agenda. The Foundation has funded over $120 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Prepared Remarks of Attorney General Michael B. Mukasey on the Justice Departments Efforts to Combat Healthcare Fraud Nationwide
2. Attorney General Michael B. Mukasey to Deliver Keynote Address at Naturalization Ceremony and Remarks on Nationwide Efforts to Combat Healthcare Fraud
3. Dr. Michael Brownlee receives JDRF Rumbough Award for Scientific Excellence
4. Michael A. Sandler, MD, Installed as President of Michigan State Medical Society
5. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
6. Michael E. DeBakey Receives Congressional Gold Medal
7. Consumers Research Council of America Names Pediatrician Michael Y. Wu, MD, MBA as One of Americas Top Pediatricians
8. Childhood Obesity Expert Dr. William Dietz Featured at the 2nd Annual Michael & Susan Dell Lectureship in Child Health
9. Michael D. Farley Appointed Chief Operating Officer of Lupus Foundation of America, Inc.
10. Michael J. Fox Foundation Commits Up to $2 Million to Improve Drug Delivery for Parkinsons Disease
11. Michael A. Giaquinto to Join Greenhill as a Managing Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the dentists ... dentistry is a fast-growing field as more patients are discovering the many different ways ... about the options currently available to them and which ones might work for their ...
(Date:4/29/2016)... ... ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a leading ... specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , A ... safety device secured by nasal surgeons onto the floor of the nasal passages, at ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market leader ... led by Eastside Partners, with participation from existing investor Martin Ventures. The ... accelerate its technology and product roadmap. , “Jvion is experiencing significant ...
(Date:4/29/2016)... ... ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of 100 on ... place for Tampa’s Best Places to Work. They were ranked in the Big Category, ... for our team,” says RMS Human Resources Manager Irene Miller. “We work hard to ...
(Date:4/29/2016)... Newport Beach, CA (PRWEB) , ... April 29, 2016 , ... ... Dr. Jane L. Frederick, Dr. Sanaz Ghazal, and Dr. Daniel A. Potter -- are ... the Society for Assisted Reproductive Technology (SART). In April, SART published the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016  While Abbott,s announced purchase ... company,s valve repair and stent business, healthcare research ... Abbott more firmly into patient monitoring.  Kalorama said ... growing device areas, with double-digit growth expected the ... Advanced Remote Patient Monitoring . Abbott ...
(Date:4/28/2016)... 28, 2016  The blood testing market in ... to Kalorama Information and The Freedonia Group in a ... acid testing.  The healthcare research firm said that ... blood collection stations and in improving testing at the ... report, Blood Testing Market in China ...
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
Breaking Medicine Technology: